we are programmmed for disease
DESCRIPTION
Novel Technologies to assess Gut Health Claims for Carbohydrates Subthema: 2 - Characterization of biological effects of carbohydrates Naam trekker: UJF Tietge / HJ Verkade Affiliatie: UMC Groningen/Dept. of Pediatrics Contactgegevens: [email protected]. gut health. programming. - PowerPoint PPT PresentationTRANSCRIPT
Novel Technologies to assess Gut Health Claims for Carbohydrates
Subthema: 2 - Characterization of biological effects of carbohydrates
Naam trekker: UJF Tietge / HJ VerkadeAffiliatie: UMC Groningen/Dept. of PediatricsContactgegevens: [email protected]
We are programmmed for disease
General theme: different carbohydrates have differential effects on the balance between health and disease by affecting the intestine at all stages of life
aging
disease
in utero
breast milkvs.
formula feeding
programming
food microbiota
e.g. SCFA
programming
food microbiota
e.g. SCFA
gut health
food microbiota
e.g. SCFA
- direct effects- modulation of programmed risk
Increasing gut health with carbohydrates at all stages of life
(13)CH
conventionalvs.
germ-freevs.
selectivere-constitution/transplantation
Disease models:- atherosclerosis- diabetes (type I and II)- NAFLD/NASH- intest. Inflammation
• in vivo screening platform
• biomarkers (disease-causing signatures of metabolites/ bacterial products)
• novel CHs to test in humans
• leads for health claims
Deliverablesprogramming
Techniques:- atherosclerosis quantitation- GTT/ITT/clamps- Histology- histology/clinical symptoms- stable isotopes to quantitate metabolic fluxes- characterization microbiota- barrier function
Mouse models
Close links to themes 1, 3 and 4
Short-term intervention:- children (lean/obese)- adults (young/elderly/IBD)
• in vivo screening routine for CHs with human relevance
• health claims based on established mechanisms
• novel biomarkers of disease including microbiota
• establish novel CHs as functional food
Deliverables
Human studies
Techniques:- GTT/clamp- biomarkers-stable isotope techniques- SCFA measurements- histology/clinical symptoms- sampling capsule to characterize:
• microbiota• barrier function
ZN Wang et al. Nature 472, 57-63 (2011)
Gut-flora-dependent metabolism of dietary PC and atherosclerosis
(13)CH
conventionalvs.
germ-freevs.
selectivere-constitution/transplantation
Disease models:- atherosclerosis- diabetes (type I and II)- NAFLD/NASH- intest. Inflammation
• in vivo screening platform
• biomarkers (disease-causing signatures of metabolites/ bacterial products)
• novel CHs to test in humans
• leads for health claims
Deliverablesprogramming
Techniques:- atherosclerosis quantitation- GTT/ITT/clamps- Histology- histology/clinical symptoms- stable isotopes to quantitate metabolic fluxes- characterization microbiota- barrier function
Mouse models
Increasing gut health with carbohydrates at all stages of life
ZN Wang et al. Nature 472, 57-63 (2011)
Gut-flora-dependent metabolism of dietary PC and atherosclerosis
Short-term intervention:- children (lean/obese)- adults (young/elderly/IBD)
• in vivo screening routine for CHs with human relevance
• health claims based on established mechanisms
• novel biomarkers of disease including microbiota
• establish novel CHs as functional food
Deliverables
Human studies
Techniques:- GTT/clamp- biomarkers- stable isotope techniques- SCFA measurements- histology/clinical symptoms- sampling capsule to characterize:
• microbiota• barrier function
(13)CH